Annovis Bio, Inc.: Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
Berwyn, Pennsylvania (Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ( Annovis or the Company ), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the Jefferies Virtual Healthcare Conference 2021 as follows:
Date: Friday, June 4, 2021
Time: 8:00 a.m. ET
Webcast: https://wsw.com/webcast/jeff174/anvs/1866024
The presentation will be webcast live and archived for 30 days thereafter.
About Annovis Bio Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer s disease (AD), Parkinson s disease (PD) and Alzheimer s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS t
Constellation Pharmaceuticals Inc (NASDAQ: CNST) is trading higher Wednesday morning after an announcement that MorphoSys AG (NASDAQ: MOR) will acquire the .
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO
About
Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead investigational product, Illuccix
® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,